Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Study: No major difference in mortality between patients treated with drug-coated and non-drug-coated devices

Peripheral artery disease (PAD), or blockages in the arteries outside of the heart, affects more than 200 million people worldwide and 12.5 million people in the United States. Patients with this circulatory disorder may develop severe leg pain or unhealing wounds that require a minimally invasive revascularization procedure to open the blood vessels to improve blood flow.

18 May 2021

New strategy could increase the effectiveness of chemotherapy treatments

New research led by a team at Massachusetts General Hospital (MGH) points to a promising strategy to boost tumors' intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.

7 May 2021

Drug synthesized from Kentucky-grown plant shows promise in treating ovarian cancer

A new study from University of Kentucky Markey Cancer researchers shows that Artemisia annua, a plant that has been traditionally used for its anti-malaria components, shows promise in treating ovarian cancer.

26 Apr 2021

Treatment resistance in triple-negative breast cancers linked to softer tissue environment

Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells.

3 Apr 2021

The Dream Team opens clinical trial to find better treatment options for pancreatic cancer

A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer patients based on the molecular traits of tumors.

30 Mar 2021

Study reveals potential risk factors for developing nerve damage after cancer treatment

A low hemoglobin count, older age and high BMI are possible risk factors for developing nerve damage after cancer treatment, a UNSW-led study has found.

4 Mar 2021

Combining PD-1 and VEGF inhibitors with chemotherapy can help control cholangiocarcinoma

Cholangiocarcinoma (CCA) is considered as a diverse group of epithelial cancers characterized by poor outcomes. Cholangiocarcinoma can be divided into three types according to the original position: Intrahepatic Cholangiocarcinoma (ICC), Perihilar Cholangiocarcinoma (PCC), and Distal Extrahepatic Tumors (DET).

3 Feb 2021

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

Study: Paclitaxel-coated devices do not increase mortality for patients with peripheral artery disease

An interim analysis from the Swedish Drug-Elution Trial in Peripheral Arterial Disease (SWEDEPAD) has now been presented.

10 Dec 2020

First-ever phase 3 advanced anal cancer trial opens for patient enrollment

The first randomized phase 3 clinical trial ever to be conducted in patients with advanced cancer of the anal canal is now open and enrolling patients.

16 Nov 2020

Study: Photoresponsive derivatives of Taxol allow light-based control of microtubule cytoskeleton

Ludwig-Maximilians-Universitaet (LMU) in Munich researchers have developed photoresponsive derivatives of the anticancer drug Taxol, which allow light-based control of cytoskeleton dynamics in neurons. The agents can optically pattern cell division and may elucidate how Taxol acts.

9 Nov 2020

Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Announcing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients.

27 Jul 2020

Researchers develop new nano drug that kills triple-negative breast cancer cells

Researchers at the University of Arkansas have developed a new nano drug candidate that kills triple negative breast cancer cells.

20 Jul 2020

Cocktail of chemotherapy drugs may be safe, effective for patients with metastatic pancreatic cancer

Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease.

8 Jul 2020

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients.

2 Jul 2020

Inflammatory changes in tumors can cause drug resistance in cancer blood vessels

Scientists at Hokkaido University and collaborators have identified how inflammatory changes in tumors caused by chemotherapy trigger blood vessel anomalies and thus drug-resistance, resulting in the poor prognosis of cancer patients.

1 Jul 2020

Combination therapy improves survival rates for women with aggressive endometrial cancer

Yale Cancer Center scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.

29 Jun 2020

International trial shows better option for treating people with inoperable anal cancer

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

24 Jun 2020

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Up to now, patients with inoperable anal cancer, a rare disease, have not had a standard-of-care treatment; palliative care has been the routine for them.

19 Jun 2020

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival (PFS) outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients.

30 May 2020